Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA3 | P07451 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | SOST | Q9BQB4 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.43 |
| ▸ | NQO1 | P15559 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | HPGD | P15428 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | MAOA | P21397 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL157615 | 0.72 | CA12 (0.47) | CA12CA1CA9LMNACA2 | |
| SCHEMBL5203164 | 0.72 | PGR (0.41) | CA12CA1CA9LMNACA2 | |
| SCHEMBL1490915 | 0.72 | CA12 (0.52) | CA12CA1CA9LMNACA2 | |
| SCHEMBL5206649 | 0.72 | PGR (0.38) | CA12CA1CA9LMNACA2 | |
| SCHEMBL5205733 | 0.69 | ALDH1A1 (0.38) | CA12CA1CA9LMNACA2 | |
| SCHEMBL961967 | 0.69 | KDM4E (0.56) | CA12CA1CA9LMNACA2 | |
| SCHEMBL453408 | 0.67 | HPGD (0.38) | CA12CA1CA9LMNACA2 | |
| SCHEMBL1385840 | 0.64 | KDM4E (0.35) | CA12CA1CA9LMNACA2 | |
| SCHEMBL8632474 | 0.63 | MCL1 (0.51) | CA12CA1CA9LMNACA3 | |
| SCHEMBL8394661 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4165033-A1 | SHP2 INHIBITORS, COMPOSITIONS AND USES THEREOF | Betta Pharmaceuticals Co., Ltd (CN) | 2023-04-19 | — | — | EP | claimed |
| WO-2021249449-A1 | SHP2 INHIBITORS, COMPOSITIONS AND USES THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2021-12-16 | — | — | WO | claimed |
| US-9174960-B2 | Compounds useful against kinetoplastideae parasites | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2015-11-03 | — | — | US | claimed |
| US-20140171455-A1 | Reduction of Microglia-Mediated Neurotoxicity by Kv1.3 Inhibition | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-06-19 | — | — | US | claimed |
| EP-2717871-A2 | REDUCTION OF MICROGLIA-MEDIATED NEUROTOXICITY BY KV1.3 INHIBITION | The Regents of the University of California (US) | 2014-04-16 | — | — | EP | claimed |
| WO-2012170917-A2 | REDUCTION OF MICROGLIA-MEDIATED NEUROTOXICITY BY KV1.3 INHIBITION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-12-13 | — | — | WO | claimed |
| US-20120214996-A1 | COMPOUNDS USEFUL AGAINST KINETOPLASTIDEAE PARASITES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-08-23 | — | — | US | claimed |
| EP-2477698-A2 | COMPOUNDS USEFUL AGAINST KINETOPLASTIDEAE PARASITES | Centre National de la Recherche Scientifique (FR) | 2012-07-25 | — | — | EP | claimed |
| US-7994323-B2 | Chromen-2-one derivatives | NEUROSEARCH A/S (DK) | 2011-08-09 | — | — | US | claimed |
| EP-2158200-B1 | NOVEL CHROMEN-2-ONE DERIVATIVES | NEUROSEARCH AS (DK) | 2011-07-13 | — | — | EP | claimed |
| US-20100217002-A1 | NOVEL CHROMEN-2-ONE DERIVATIVES | NEUROSEARCH A/S (DK) | 2010-08-26 | — | — | US | claimed |
| EP-2158200-A1 | NOVEL CHROMEN-2-ONE DERIVATIVES | NeuroSearch A/S (DK) | 2010-03-03 | — | — | EP | claimed |
| WO-2008138854-A1 | NOVEL CHROMEN-2-ONE DERIVATIVES | NEUROSEARCH A/S (DK) | 2008-11-20 | — | — | WO | claimed |
| EP-0998474-B1 | PIPERAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2007-02-07 | — | — | EP | claimed |
| WO-2006098624-A2 | ANTI-VIRAL USE OF A COUMARIN AGENT | RADEMAKER HOLDING B.V. (NL) | 2006-09-21 | — | — | WO | claimed |
| WO-2006098620-A1 | USE OF DERIVATIVES COMPRISING A COUMARIN GROUP FOR THE PREPARATION OF AN ANTIVIRAL AGENT, DERIVATIVES COMPRISING A COUMARIN GROUP, A METHOD FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | RADEMAKER HOLDING B.V. (NL) | 2006-09-21 | — | — | WO | claimed |
| EP-0853628-B1 | PHOTOLABILE 8-SUBSTITUTED CYCLIC NUCLEOTIDE ESTERS, METHODS OF PREPARING THEM AND THEIR USE | FORSCHUNGSVERBUND BERLIN EV (DE) | 2002-10-02 | — | — | EP | claimed |
| US-6251908-B1 | Piperazine derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2001-06-26 | — | — | US | claimed |
| EP-0998474-A1 | PIPERAZINE DERIVATIVES | MERCK PATENT GmbH (DE) | 2000-05-10 | — | — | EP | claimed |
| WO-1999003855-A1 | PIPERAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 1999-01-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171455-A1 | Reduction of Microglia-Mediated Neurotoxicity by Kv1.3 Inhibition | KCNMA1, KCNN1, KCNN3 | CA12 1272/4885CA1 58/4885CA9 2983/4885 |
| US-20120214996-A1 | COMPOUNDS USEFUL AGAINST KINETOPLASTIDEAE PARASITES | TST, PDXK, TBCB | CA12 4875/4885CA1 4879/4885CA9 4862/4885 |
| US-20100217002-A1 | NOVEL CHROMEN-2-ONE DERIVATIVES | CBX2, CYP2J2, CDYL2 | CA12 1775/4885CA1 4334/4885CA9 4022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.